These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 20816372)

  • 21. Review of current literature and implications of RANKL inhibitors for oral health care providers.
    Epstein MS; Ephros HD; Epstein JB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2013 Dec; 116(6):e437-42. PubMed ID: 22901640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Denosumab for the treatment of giant cell tumor of the bone.
    Brodowicz T; Hemetsberger M; Windhager R
    Future Oncol; 2015; 11(13):1881-94. PubMed ID: 26161925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Osteonecrosis of the jaws induced by anti-RANK ligand therapy.
    Taylor KH; Middlefell LS; Mizen KD
    Br J Oral Maxillofac Surg; 2010 Apr; 48(3):221-3. PubMed ID: 19836866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Denosumab in the prevention of skeletal-related events in patients with bone metastases from solid tumors: profile report.
    Scott LJ; Muir VJ
    BioDrugs; 2011 Dec; 25(6):397-400. PubMed ID: 22050342
    [No Abstract]   [Full Text] [Related]  

  • 25. Osteonecrosis of the jaw in a patient on Denosumab.
    Aghaloo TL; Felsenfeld AL; Tetradis S
    J Oral Maxillofac Surg; 2010 May; 68(5):959-63. PubMed ID: 20149510
    [No Abstract]   [Full Text] [Related]  

  • 26. Denosumab treatment of giant cell tumour of bone.
    Balke M
    Lancet Oncol; 2013 Aug; 14(9):801-2. PubMed ID: 23867210
    [No Abstract]   [Full Text] [Related]  

  • 27. RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?
    Van den Wyngaert T; Wouters K; Huizing MT; Vermorken JB
    Support Care Cancer; 2011 Dec; 19(12):2035-40. PubMed ID: 21203781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bevacizumab (Avastin): An anti-angiogenic drug associated with osteonecrosis of the jaw.
    Wynn RL
    Gen Dent; 2011; 59(6):410-3. PubMed ID: 22313910
    [No Abstract]   [Full Text] [Related]  

  • 29. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL; Hansen RL; Jørgensen PH
    Ugeskr Laeger; 2016 Sep; 178(36):. PubMed ID: 27593237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab: second chapter in controlling bone metastases or a new book?
    Fornier MN
    J Clin Oncol; 2010 Dec; 28(35):5127-31. PubMed ID: 21060038
    [No Abstract]   [Full Text] [Related]  

  • 32. Giant cell tumour of bone in the denosumab era.
    van der Heijden L; Dijkstra PDS; Blay JY; Gelderblom H
    Eur J Cancer; 2017 May; 77():75-83. PubMed ID: 28365529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy.
    Vignot S; Khayat D
    J Clin Oncol; 2009 Apr; 27(10):1534-6. PubMed ID: 19237628
    [No Abstract]   [Full Text] [Related]  

  • 34. Denosumab: An Alternative Therapy for the Management of Giant Cell Lesions.
    O'Connell JE; Kearns GJ
    J Oral Maxillofac Surg; 2016 May; 74(5):873. PubMed ID: 26899479
    [No Abstract]   [Full Text] [Related]  

  • 35. Giant cell tumor of bone in childhood: clinical aspects and novel therapeutic targets.
    Federman N; Brien EW; Narasimhan V; Dry SM; Sodhi M; Chawla SP
    Paediatr Drugs; 2014 Feb; 16(1):21-8. PubMed ID: 24114694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
    Lau CP; Huang L; Wong KC; Kumta SM
    Connect Tissue Res; 2013; 54(6):439-49. PubMed ID: 24060052
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Giant cell tumour of bone.
    Thomas DM; Skubitz KM
    Curr Opin Oncol; 2009 Jul; 21(4):338-44. PubMed ID: 19444102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Osteonecrosis of the jaw related to bevacizumab.
    Estilo CL; Fornier M; Farooki A; Carlson D; Bohle G; Huryn JM
    J Clin Oncol; 2008 Aug; 26(24):4037-8. PubMed ID: 18711196
    [No Abstract]   [Full Text] [Related]  

  • 39. New developments for treatment and prevention of bone metastases.
    Body JJ
    Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Denosumab in osteoporosis and oncology.
    Burkiewicz JS; Scarpace SL; Bruce SP
    Ann Pharmacother; 2009 Sep; 43(9):1445-55. PubMed ID: 19622756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.